Population Health Management of Chronic Kidney Disease (CKD)

Jeffrey Feldman, MD, and Rajiv Agarwal, MD, MS, provide an overview of chronic kidney disease (CKD) and its prevalence.

Dr Feldman describes the populations that are most at risk of developing CKD.

Paul Sapia, MHA, focuses on the gaps in care that are seen within CKD treatment.

Drs Feldman and Agarwal consider the health disparities commonly seen with patients that have CKD and their impact in the treatment landscape.

Paul Sapia, MHA, explains the economic burden of treating chronic kidney disease.

Jeffrey Feldman, MD, details the clinical burden of CKD management, and Bertram Pitt, MD, discusses the impact CKD can have on patients at risk for cardiovascular disease.

Dr Rajiv Agarwal explains the screening process for patients with CKD, including those who are asymptomatic.

Paul Sapia, MHA, acknowledges the underdiagnosis in CKD and explains how payers can incentivize screening going forward.

Jeffrey Feldman, MD, describes the treatment goals for patients with CKD.

Drs Agarwal and Pitt begin an overview of the CKD treatment landscape, beginning with the importance of blood pressure management.

Dr Feldman concludes the treatment landscape overview by discussing glycemic control, SGLT2 inhibitors, and other important management techniques.

Dr Agarwal provides a deep dive into the use of nonsteroidal mineralocorticoid receptor antagonists in CKD therapy.

Dr Jeffrey Feldman discusses finerenone trial data and the role that it and SGLT2 inhibitors have played in patients with CKD.

Dr Bertram Pitt explains the possibility of combining SGLT2 inhibitors and MRAs when treating CKD and CV, and Paul Sapia, MHA, discusses how payers balance cost of care with disease progression and health disparities.

Drs Feldman, Pitt, and Agarwal describe the common CKD health disparities seen at their institutions and the steps they have taken to address them.

The esteemed panel concludes with their final thoughts on CKD therapies and management.